anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The initial assessment, comprising 25 items, will be administered to participants who have been randomly assigned to the control group. This group will be invited to attend a seminar at our clinic, during which a PowerPoint presentation will be delivered. Following the conclusion of the presentation, the same assessment will be repeated, and the participant's initial and second scores will be recorded in the case report form.
<P>PROBLEM TO BE SOLVED: To provide a composition and a method for diagnosis and treatment of the growth and proliferation of tumor cells in mammals including human beings.  <P>SOLUTION: A gene to be amplified is identified in the genome of the tumor cell. The gene amplification relates to the excess expression of a gene product compared to a normal cell having the same tissue form, and it is predicted that the amplification contributes to tumor formation. As a result, the protein encoded by the amplified gene is considered to be useful for diagnosis and/or treatment (including prevention) of some kind of cancer, and acts so as to predict the prognosis of tumor treatment. The new polypeptide and the nucleic acid encoding the polypeptide are provided. The vector containing the nucleic acid sequence, the host cell, the chimera polypeptide molecule containing the polypeptide fused with a different kind of a polypeptide sequence, the antibody binding to the polypeptide, and the method for producing the polypeptide are also provided.  <P>COPYRIGHT: (C)2003,JPO
Diabetic nephropathy is one of the complications of diabetes that affects the kidney and can result in renal failure. The cholesterol-lowering drug simvastatin (SIM) has shown promising effects against diabetic nephropathy (DN). This study evaluated the protective role of SIM on DN, pointing to the involvement of farnesoid X receptor (FXR) and Nrf2/HO-1 signaling in attenuating inflammatory response, oxidative injury, and tissue damage in streptozotocin-induced diabetic rats. SIM was supplemented orally for 8 weeks, and samples were collected for analysis. SIM effectively ameliorated hyperglycemia, kidney hypertrophy, body weight loss, and tissue injury and fibrosis in diabetic animals. SIM mitigated oxidative stress (OS), inflammatory response, and cell death, as evidenced by the suppressed malondialdehyde, nitric oxide, myeloperoxidase, NF-kB, TNF-α, IL-1β, CD68, Bax, and caspase-3 in the diabetic kidney. These effects were linked to suppressed Keap1, upregulated FXR, Nrf2, and HO-1, and enhanced antioxidant defenses and Bcl-2. The in silico findings revealed the binding affinity of SIM with NF-kB, caspase-3, Keap1, HO-1, and FXR. In conclusion, SIM protects against DN by attenuating hyperglycemia, kidney injury, fibrosis, inflammation, and OS, and upregulating antioxidants, FXR, and Nrf2/HO-1 signaling.
PROBLEM TO BE SOLVED: To obtain a masking composition free from the occurrence of unpleasant tastes such as bitterness and astringency even in the case of a little shellac content at a low cost by coating a specific material to be masked, with a specific amount of shellac. SOLUTION: This composition is obtained by kneading (A) a material to be masked consisting of chitosan and/or a chitosan oligo sugar and (B) shellac, which is a natural resin separated from stick lac of a secretion of Laceifer lacca, of less than the equal amount to the component A, preferably >=1 and <100 pts.wt. based on 100 pts.wt. of the component A to coat the component A with the component B. Concretely, the components A and B, and a solvent such as ethanol are mixed to obtain a homogeneously dispersed kneaded product. The product is coagulated and dried optionally by heating and treating under reduced pressure, subsequently crushed and pulverized, and sifted through a sieve such as a screen, and as a result, the objective composition consisting of articles preferably having particle sizes of 0.1-0.5 mm is obtained.
All participants will receive cWGS testing revealed to the site PI/clinician at Day 180. Participants will all receive standard of care testing throughout the study.
FIELD: virology, veterinary science. SUBSTANCE: industrial strain N 1707 "Armenia-98" is obtained by multiple successive passages on sensitive hetero- and homologous cell cultures. The strain is deposited in Collection of microorganisms VGNKI at N 1707 "Armenia-98-DEP". The strain N 1707 "Armenia-98" is distinguished from both industrial and early isolated epizootic strains of foot and mouth virus disease type A. Virus of the strain N 1707 "Armenia-98" is reproduced in sensitive cell cultures and its accumulation for 20-24 h of incubation is up to 7.0-8.0 lg TTC 50 /ml. The strain induces TSPD in 4 h after massive infection, retains the parent indices at passage in cell cultures for 10 passages. New industrial foot and mouth virus disease type A strain shows high biological, antigenic and immunogenic activity and can be used for preparing agents for specific prophylaxis and diagnosis of foot and mouth virus disease type A showing homology to epizootic virus in Transcaucasis and Near East countries. EFFECT: new strain of virus indicated above, improved properties and activity. 2 dwg, 8 tbl, 5 ex
Cardiac rehabilitation (CR), a formalized exercise and behavioral modification program, is the cornerstone of secondary prevention for heart disease. Implementation of CR early after an acute myocardial infarction (MI) is associated with improved cardiac function and survival. As such, CR is now standard of care for a majority of hospital-based discharge programs following coronary events. In stark contrast, no similar program exists following an acute venous thromboembolism (VTE or blood clot), despite a high rate of limb and respiratory disability after VTE, shared risk factors with heart disease, and known beneficial impact of exercise training on VTE complications (e.g. post-thrombotic syndrome, PTS).

Body weight is a key modifiable risk factor driving risk of incident and recurrent VTE. Obese patients with prior VTE have a 2-fold higher risk of a second VTE compared to normal weight patients.(1) Importantly, VTE recurrence risk escalates if weight control is not established. Weight gain after acute DVT is common, with a mean 7% increase over 6 months.(2) To date, however, there is limited evidence regarding whether early initiation of exercise training following acute DVT is safe and feasible and mitigates weight gain associated with a VTE diagnosis. Previously, a significant decrease in body weight and fat mass loss was demonstrated utilizing high-caloric expenditure exercise in the CR setting.(3) Delineating the impact of high-caloric expenditure exercise to induce weight loss and reduce VTE complications and recurrence is a critical first step toward evaluating the role of early post-VTE rehabilitation in the clinical setting.
The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF.alpha.. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitables as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.
Child drowning is a significant public health issue in Indonesia, however, there is insufficient understanding of the issue and its associated risk factors within communities. This qualitative study aimed to explore parental and community perceptions and practices related to child drowning in Indonesian communities, and the perceived causes and risk factors. Seven focus group discussions (n = 62) were conducted with parents of children aged under-5 years and village community leaders in seven villages across all districts of Lombok Island, West Nusa Tenggara Province of Indonesia. Participants were recruited using purposive and snowball sampling. The thematic analysis, guided by Braun and Clarke's framework, used both deductive approaches, utilizing the Health Belief Model's constructs and inductive approaches. Most participants were unaware of the susceptibility of their children and others in their community to drowning and of the potential severe outcomes of drowning such as injury, disability and death. Participants generally associated drowning with beaches or open seas. Unprotected wells, tubs and buckets were identified as notable risk factors for child drowning in and around the home, shaped by some experience of child drowning incidents in the community. Supervision was identified as protective factor, however, mothers were often unavailable to supervise children, and supervision responsibility was often delegated to other family and community members. This study highlights the urgent need to enhance public awareness regarding children's susceptibility to drowning. Further exploration of local contexts and social determinants of drowning in Indonesian communities is crucial for ensuring effective water safety and drowning prevention strategies.
PURPOSE:To obtain a blood flow improver containing a thrombin-like enzyme, especially a sugar chain-treated material of batroxobin, namely, batroxobin whose sugar chain is modified as an active ingredient and useful for various kinds of diseases caused by lowering of fluidity of blood, staying, etc., of blood. CONSTITUTION:This blood improver contains a sugar chain treated material of batroxobin whose sugar chain is cleaved as an active ingredient. The sugar chain treated material of batroxobin include, especially preferably, an enzyme- treated material of batroxobin. Further, as the enzyme used, glycosidase, especially sialidase or beta-N-acetylhexosaminidase is preferably used. Asialo batroxobin is obtained by treating batroxobin with sialidase. M3-batroxobin is obtained by treating batroxobin with sialidase and beta-N-acetylhexosaminidase. In this method, enzymatic activity of batroxobin is unchanged or increased by digesting batroxobin with exoglycosidase and blood concentration can be suppressed by properly administering the digested batroxobin.
BACKGROUND & AIMS: Concurrent hepatic steatosis has diverse effects on chronic hepatitis B (CHB), however the combined effects of metabolic dysfunction-associated steatotic liver disease (MASLD) and CHB on liver fibrosis progression remains unclear. The primary aim of this study was to utilize serial fibrosis measurements to compare the dynamic change in fibrosis in CHB patients with/without concurrent MASLD. The secondary aim was to investigate factors associated with steatosis development and regression in CHB patients.
METHODS: This was a retrospective cohort study of all non-cirrhotic CHB patients identified from 1/1/2011 to 31/12/2016. Hepatic steatosis was diagnosed by ultrasound. Fibrosis markers included liver stiffness (LSM) by transient elastography, APRI and FIB-4. General linear mixed effects modelling was used to fit polynomial and linear estimates.
RESULTS: Of 810 CHB patients (n = 2,373 LSM measurements; median age 44.4y; 48% male; 24% HBeAg positive), 14% had concurrent MASLD. LSM was higher at baseline but decreased in MASLD patients over time, while LSM remained stable in non-MASLD patients, such that all patients had similar LSM beyond 4-5 years. MASLD patients had lower APRI compared to non-MASLD patients, which was predominately due to a higher platelet count and higher ALT over time. There was substantial discordance between LSM, APRI and FIB-4. Baseline BMI was the only factor that predicted steatosis development and regression.
CONCLUSIONS: We found no evidence of an association between concurrent MASLD and fibrosis progression amongst CHB patients without baseline advanced liver disease. APRI and FIB-4 may have reduced accuracy in MASLD patients.
This two-arm randomized study will evaluate an "unaware intervention package" among HIV-infected persons attending Sexually Transmitted Infection (STI) clinics in Lilongwe, Malawi. The package includes detection of Acute HIV Infection (AHI), contract partner notification, and social contact referral to find persons unaware of their HIV infection. The package will be compared to the current standard of care, passive partner notification, as the base case. Participants will be randomized to receive the intervention package - classified as the "active arm" of the study. The study will characterize the HIV stage (acute, recent, chronic) of the index participants and their sexual partners and social contacts, and use the HIV staging combined with sexual behavior data, phylogenetic analyses, and egocentric sexual/social network assessments to assess the potential impact of the intervention on ongoing transmission. We will obtain the distributions of numerous transmission-related attributes among the recruited contacts/partners of STI clinic patients, including contacts' and partners' HIV infection status and stage, HIV diagnosis/care/treatment status, STI status, and sexual behaviors. This information will allow us to model testing, linkage, and treatment interventions targeted to the traced partners and/or social contacts of acute, recent, and/or chronic index cases identified in STI clinics. We can then assess and compare the predicted effects on population-level HIV incidence of interventions attached to each recruitment method (tracing partners, social contacts, or both) and index case and contact disease stage (acute, recent, and/or chronic).
BACKGROUND AND OBJECTIVE: Stroke is a disease with high mortality and disability. Importantly, the fatality rate demonstrates a significant increase among patients afflicted by recurrent strokes compared to those experiencing their initial stroke episode. Currently, the existing research encounters three primary challenges. The first is the lack of a reliable, multi-omics image dataset related to stroke recurrence. The second is how to establish a high-performance feature extraction model and eliminate noise from continuous magnetic resonance imaging (MRI) data. The third is how to integration multi-omics data and dynamically weighted for different omics data.
METHODS: We systematically compiled MRI and conventional detection data from a cohort comprising 737 stroke patients and established PSTSZC, a multi-omics dataset for predicting stroke recurrence. We introduced the first-ever Integrated Multi-omics Prediction Model for Stroke Recurrence, MPSR, which is based on ResNet, Lnet-transformer, LSTM and dynamically weighted DNN. The MPSR model comprises two principal modules, the Feature Extraction Module, and the Integrated Multi-Omics Prediction Module. In the Feature Extraction module, we proposed a novel Lnet regularization layer, which effectively addresses noise issues in MRI data. In the Integrated Multi-omics Prediction Module, we propose a dynamic weighted mechanism based on evaluators, which mitigates the noise impact brought about by low-performance omics.
RESULTS: We compared seven single-omics models and six state-of-the-art multi-omics stroke recurrence models. The experimental results demonstrate that the MPSR model exhibited superior performance. The accuracy, AUROC, specificity, and sensitivity of the MPSR model can reach 0.96, 0.97, 1, and 0.94, respectively, which is higher than the results of contrast model.
CONCLUSION: MPSR is the first available high-performance multi-omics prediction model for stroke recurrence. We assert that the MPSR model holds the potential to function as a valuable tool in assisting clinicians in accurately diagnosing individuals with a predisposition to stroke recurrence.
PURPOSE:To obtain a drug preparation for external use, having excellent transferability of germanium dioxide to diseased part, enabling the decrease of the amount of germanium dioxide in the drug and useful for the remedy of myositis, arthritis, etc., by mixing an aqueous solution of germanium dioxide with a base. CONSTITUTION:The objective drug preparation for external use can be produced by mixing an aqueous substance of germanium dioxide with a drug base. The aqueous solution can be produced by heating and completely melting germanium dioxide at >=1,100 deg.C preferably 1,100-1,200 deg.C and dissolving the obtained amorphous glassy germanium dioxide in water to obtain a uniform aqueous solution. The mixing of germanium dioxide in the form of an aqueous solution enables the improvement of the transferability of germanium dioxide to the diseased part, the remarkable reduction of the amount of expensive germanium dioxide and the production of a safe external drug. The content of germanium dioxide in the drug is preferably 0.1-1.0wt%. It mitigates the symptoms of especially tenonitis, ligamentitis, arthritis and periostitis.
The present invention relates to a slow-released injection containing vasoinhibitor and its synergist. It is composed of slow-released microsphere and solvent, in which the slow-released microsphere includes anticancer effective component and slow-released auxiliary material, the solvent is a special one containing suspension adjuvant. The anticancer effective component includes vasoinhibitor of vascular endocolyone, elotine, lapatine and pelitine and/or vasoinhibitor synergist selected from topoisomerase inhibitor and/or tetrazine compound; the slow-released auxiliary material is one selected from sebacic acid copolymer, EVAc. racemic polylactic acid and its copolymer, monomethyl polyethylene glycol and its copolymer, polyethylene glycol/polylactic acid copolymer, carboxyl terminated polylactic acid or carboxyl terminated palylactic acid/glycolic acid copolymer or their combination; the viscosity of suspension adjuvant is 100 cp-3000 cp. said suspension adjuvant is selected from sodium cellulose glycollate. The slow-released microsphere also can be made into slow-released implant preparation.
Internet-delivered cognitive behavior therapy for social anxiety disorder has previously demonstrated to target and affect the brain´s fear network, typically neural response in the amygdala ameliorate after effective psychological treatment. Commonly, neuroimaging studies have performed brain imaging at pre- and post-intervention, yet, longitudinal study designs including several repeated measures of neural response over the course of treatment are currently missing in anxiety disorder. In the current study the participants will undergo magnetic resonance imaging (MRI) at four occasion. a) Twice before treatment initiation (9 weeks apart), b) at week 4 (during treatment), c) and directly after treatment termination.

Biological aging can be quantified at the individual cell level by measuring telomere length in peripheral immune cells (leukocytes). Telomeres are located at the end of each chromosome and protect the genetic material during cell division. Telomerase is an enzyme that can lengthen telomeres, and have in this way a protective function against accelerated cellular aging. Variations in these bodily processes have been associated with psychiatric manifestations such as anxiety and depression. In the current study the participant´s telomere length and telomerase activity will be assessed at three occasion. a) Twice before treatment initiation (9 weeks apart), and b) directly after treatment termination.
Bipolar disorder is a serious mental illness that causes drastic shifts in a person's mood, energy, and ability to function. Bipolar disorder can strike at any age, but it most commonly develops in late adolescence or early adulthood. The disorder is characterized by alternating episodes of mania and depression, often with periods of normal mood in between. Some symptoms of a manic episode include the following behaviors: increased energy, activity, and restlessness; excessively "high," overly good, euphoric mood; and extreme irritability. In contrast, a depressive episode is characterized by a lasting sad, anxious, or empty mood; feelings of hopelessness or pessimism; and decreased energy. Adolescents with bipolar disorder have high rates of disease recurrence, suicide attempts, functional impairment, and mental health service utilization, even with aggressive treatment with mood stabilizers and antipsychotic drugs. Research has suggested that FFT, a behavioral intervention consisting of psychoeducation, communication training, and problem solving training, may lead to improvements in mood symptoms in adolescents with bipolar disorder. This study will evaluate the effectiveness of FFT plus pharmacotherapy in treating adolescents with bipolar illness.

Participants in this 2-year, single-blind study will be randomly assigned to receive a combination of either FFT and pharmacotherapy or enhanced care and pharmacotherapy. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed. All participants will receive pharmacotherapy for the full 2 years. Participants assigned to enhanced care will take part in weekly brief psychoeducation sessions for 3 weeks. Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Both FFT and enhanced care treatment sessions will include psychoeducation focusing on appropriate ways to manage bipolar disorder and its cycling nature. Crisis intervention sessions will also be offered to all participants on an as-needed basis for the duration of the study. Outcomes, including bipolar disorder symptoms, functioning, and service utilization, will be measured at study visits at Months 3, 6, 9, 12, 18, and 24.
Insulin glargine is a long-acting human insulin analog produced by recombinant DNA technology utilizing a nonpathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines remain at the C-terminus of the B-chain. Insulin glargine has a molecular weight of 6063 Da.

TOUJEO (insulin glargine) injection is a sterile, clear and colorless solution for subcutaneous injection. Each mL of TOUJEO contains 300 units of insulin glargine dissolved in a clear aqueous fluid.

The 1.5 mL TOUJEO SoloStar prefilled pen presentation contains the following inactive ingredients per mL: glycerin (20 mg), metacresol (2.7 mg), zinc (90 mcg), and Water for Injection, USP.

The 3 mL TOUJEO Max SoloStar prefilled pen presentation contains the following inactive ingredients per mL: glycerin (20 mg), metacresol (2.7 mg), zinc (90 mcg), and Water for Injection, USP.

The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. TOUJEO has a pH of approximately 4.